The revenue guidance cut is the dominant signal here, confirming structural headwinds in US Orthopaedics and wound bioactives. While management maintained profit guidance through cost cuts, this is not sustainable for multiple expansion. Monitor Q3 trading report on Nov 6 for evidence of the promised H2 revenue acceleration (5.0-5.5% underlying growth) and US Knee/Hip implant trajectory.
Price Chart
Executive Summary
Smith+Nephew reported H1 2026 revenue of $3,097M (+4.6% reported, +2.3% underlying) and trading profit of $566M (+8.1%), but cut full-year underlying revenue growth guidance from ~6% to ~4%, citing softness in US Orthopaedics and Advanced Wound Bioactives. While trading profit, free cash flow, and ROIC guidance were maintained via cost cuts, the revenue guidance reduction is a material negative signal that overshadows the profit beat.
Key Facts
- H1 2026 revenue was $3,097M, up 4.6% reported / 2.3% underlying vs H1 2025.
- Full-year underlying revenue growth guidance cut from ~6% to ~4%.
- H1 trading profit was $566M, up 8.1% vs H1 2025; trading profit margin up 60bps to 18.3%.
- Q2 2026 revenue was $1,597M, with underlying growth of just 1.6%.
- US revenue declined -1.2% in Q2; US Orthopaedics revenue declined -1.0% underlying.
- Advanced Wound Bioactives revenue fell -12.7% underlying in Q2 due to skin substitute reimbursement changes.
- A $500M share buyback was announced in May; $216M settled as of Aug 3.
- Interim dividend increased 4.0% to 15.6 per share.
- Net debt was $3,019M at June 27, 2026; adjusted leverage ratio 1.8x.
- Acquisition of Integrity Orthopaedics completed in Jan 2026 for $390M total consideration.
Financial Impact
Full-year revenue guidance cut from ~6% to ~4% underlying growth, implying roughly $120-150M less revenue than previously expected at the midpoint. Trading profit guidance maintained at ~$1.3B via $50M in additional cost savings.
Risk Factors
- US Orthopaedics revenue declining (-1.0% underlying in Q2) with no clear near-term catalyst for reversal.
- Advanced Wound Bioactives revenue declining -12.7% underlying in Q2; skin substitute headwind expected at upper end of $20-40M range.
- Revenue guidance cut may signal deeper market share loss or demand weakness beyond temporary factors.
- Integrity Orthopaedics acquisition expected to be marginally dilutive to trading profit in 2026.
- Net debt increased to $3,019M from $2,759M at year-end 2025, partly due to buyback and acquisition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-096410 |
| Document: 0001104659-26-096410-index-headers.html | 0001104659-26-096410 |
| Document: 0001104659-26-096410-index.html | 0001104659-26-096410 |
| Document: 0001104659-26-096410.txt | 0001104659-26-096410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 11, 2026 21d ago | 6-K | $27.50 $27.56 | ▲ +0.22% | ▲ +0.44% | $26.42 (−3.93%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 9, 2026 23d ago | 6-K | $27.80 $28.06 | ▲ +0.94% | ▲ +1.27% | $26.42 (−4.96%) |
Sep 8, 2026 24d ago | 424B5 | $27.87 $28.01 | ▲ +0.50% | ▲ +1.62% | $26.42 (−5.20%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 1, 2026 4w ago | 6-K | $28.97 $27.80 | ▼ −4.04% | ▼ −4.12% | $26.42 (−8.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access